Follow
Badreddin Edris
Badreddin Edris
Stanford University School of Medicine
Verified email at stanford.edu
Title
Cited by
Cited by
Year
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
SB Willingham, JP Volkmer, AJ Gentles, D Sahoo, P Dalerba, SS Mitra, ...
Proceedings of the National Academy of Sciences 109 (17), 6662-6667, 2012
15762012
Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma
B Edris, K Weiskopf, AK Volkmer, JP Volkmer, SB Willingham, ...
Proceedings of the National Academy of Sciences 109 (17), 6656-6661, 2012
2952012
Transcriptional profiling of long non-coding RNAs and novel transcribed regions across a diverse panel of archived human cancers
AL Brunner, AH Beck, B Edris, RT Sweeney, SX Zhu, R Li, K Montgomery, ...
Genome biology 13 (8), 1-13, 2012
2692012
The macrophage colony-stimulating factor 1 response signature in breast carcinoma
AH Beck, I Espinosa, B Edris, R Li, K Montgomery, S Zhu, S Varma, ...
Clinical cancer research 15 (3), 778-787, 2009
2172009
Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling
AH Beck, CH Lee, DM Witten, BC Gleason, B Edris, I Espinosa, S Zhu, ...
Oncogene 29 (6), 845-854, 2010
1542010
ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour
B Edris, I Espinosa, T Mühlenberg, A Mikels, CH Lee, SE Steigen, S Zhu, ...
The Journal of pathology 227 (2), 223-233, 2012
1022012
Inactivation of the RB family prevents thymus involution and promotes thymic function by direct control of Foxn1 expression
PM Garfin, D Min, JL Bryson, T Serwold, B Edris, CC Blackburn, ...
Journal of Experimental Medicine 210 (6), 1087-1097, 2013
682013
Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth
B Edris, SB Willingham, K Weiskopf, AK Volkmer, JP Volkmer, ...
Proceedings of the National Academy of Sciences 110 (9), 3501-3506, 2013
602013
CSF1 expression in nongynecological leiomyosarcoma is associated with increased tumor angiogenesis
I Espinosa, B Edris, CH Lee, HW Cheng, CB Gilks, Y Wang, ...
The American journal of pathology 179 (4), 2100-2107, 2011
492011
The epidemiology of desmoid tumors in Denmark
M Anneberg, HML Svane, J Fryzek, G Nicholson, JB White, B Edris, ...
Cancer Epidemiology 77, 102114, 2022
372022
A role for versican in the development of leiomyosarcoma
PA Keire, SL Bressler, JM Lemire, B Edris, BP Rubin, M Rahmani, ...
Journal of Biological Chemistry 289 (49), 34089-34103, 2014
352014
Comparative Gene Expression Profiling of Benign and Malignant Lesions Reveals Candidate Therapeutic Compounds for Leiomyosarcoma
B Edris, JA Fletcher, RB West, M van de Rijn, AH Beck
Sarcoma 2012, 2012
242012
Compositions of antibody construct-agonist conjugates and methods of use thereof
PA Thompson, B Edris
US Patent App. 15/173,075, 2017
172017
Compositions of antibody construct-agonist conjugates and methods of use thereof
PA Thompson, B Edris
US Patent App. 15/624,441, 2017
162017
Flipping the script on macrophages in leiomyosarcoma
B Edris, K Weiskopf, IL Weissman, M van de Rijn
OncoImmunology 1 (7), 1202-1204, 2012
102012
A comparison of the Oligomap and TargetScan algorithms for miRNA target analysis
B Edris
Bmi231. stanford. edu, 2011
72011
Antibody conjugates of immune-modulatory compounds and uses thereof
PA Thompson, B Edris, CA Coburn, PR Baum, V Odegard
WO Patent App. WO2018227018A1, 2018
62018
Analysis and Targeting of ROR2 in Cancer
R Nusse, B Edris
US Patent 20,140,322,234, 2014
62014
Analysis and Targeting of ROR2 in Cancer
R Nusse, B Edris
US Patent 20,140,322,234, 2014
62014
Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors
B Edris, S Willingham, K Weiskopf, AK Volkmer, JP Volkmer, ...
OncoImmunology 2 (6), e24452, 2013
62013
The system can't perform the operation now. Try again later.
Articles 1–20